Arrr, what be the fate o' them Factor XI scallywags in the heart's wild seas o' AF?
2024-12-11
Arrr, me hearties! The treasure of a grand future in stroke risk be sunk when asundexian met its doom agin' apixaban in the OCEANIC-AF trial. But fear not, is the notion of factor XI inhibition dead in the water? Experts be chattin'! <br> *Medscape Medical News*
Avast ye heart-savvy scallywags! Gather 'round, for I’ve a tale of dashed hopes and thwarted dreams in the treacherous waters of stroke risk management, particularly for those cursed with atrial fibrillation! Aye, the mighty asundexian set sail, believing it could best the fearsome apixaban in the OCEANIC-AF trial. But lo and behold, the winds changed, and asundexian found itself sinking faster than a ship with a cannonball in its hull!But fear not, me hearties! The grand concept of factor XI inhibition be not yet buried at sea! Nay, experts in their finery gather to parley and ponder whether this noble pursuit be worth another voyage across the stormy seas of medical discovery. Could there be treasure still hidden in the depths of factor XI inhibition? Aye, only time will tell!
So hoist the sails, me mateys! While asundexian may be resting with the fishes, the spirit of innovation shall not be so easily vanquished! Let us toast to future adventures and discoveries yet to come, for in the world of medicine, there be always another horizon to chase—even if this time it be a bit more treacherous than a kraken-infested sea!